CR20170067A - Anticuerpos anti-vasa y metodos de producción y uso de los mismos - Google Patents

Anticuerpos anti-vasa y metodos de producción y uso de los mismos

Info

Publication number
CR20170067A
CR20170067A CR20170067A CR20170067A CR20170067A CR 20170067 A CR20170067 A CR 20170067A CR 20170067 A CR20170067 A CR 20170067A CR 20170067 A CR20170067 A CR 20170067A CR 20170067 A CR20170067 A CR 20170067A
Authority
CR
Costa Rica
Prior art keywords
vasa
mabs
methods
production
same
Prior art date
Application number
CR20170067A
Other languages
English (en)
Inventor
David T Weaver
Bo Zhang
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of CR20170067A publication Critical patent/CR20170067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se divulgan anticuerpos anti-VASA (mAbs), particularmente mAbs humanizados que se unen específicamente a VASA con alta afinidad.Se proporcionan las secuencias de aminoácidos de los CDRs de cadenas ligeras y cadenas pesadas, así como secuencias de consenso para estos CDRs, de estos mAbs anti-VASA.La divulgación también proporciona moléculas de ácido nucleico que codifican los mAbs anti-VASA, vectores de expresión, células huésped, métodos para hacer los mAbs anti-VASA y métodos para expresar los mAbs anti-VASA.Finalmente, se divulgan métodos para usar los mAbs anti-VASA para aislar y/o purificar las células que expresan VASA.
CR20170067A 2014-09-16 2015-09-16 Anticuerpos anti-vasa y metodos de producción y uso de los mismos CR20170067A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
CR20170067A true CR20170067A (es) 2017-05-10

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170067A CR20170067A (es) 2014-09-16 2015-09-16 Anticuerpos anti-vasa y metodos de producción y uso de los mismos

Country Status (26)

Country Link
US (4) US9403913B2 (es)
EP (1) EP3194448A4 (es)
JP (2) JP2017532953A (es)
KR (1) KR20170056521A (es)
CN (1) CN106573985A (es)
AP (1) AP2017009758A0 (es)
AU (1) AU2015317813B2 (es)
BR (1) BR112017003263A2 (es)
CA (1) CA2959179A1 (es)
CL (1) CL2017000402A1 (es)
CO (1) CO2017001724A2 (es)
CR (1) CR20170067A (es)
DO (1) DOP2017000050A (es)
EA (1) EA201790236A1 (es)
EC (1) ECSP17011262A (es)
GT (1) GT201700036A (es)
IL (1) IL250451A0 (es)
MX (1) MX358243B (es)
NI (1) NI201700022A (es)
PE (1) PE20170667A1 (es)
PH (1) PH12017500309A1 (es)
SG (1) SG11201701016WA (es)
SV (1) SV2017005393A (es)
TN (1) TN2017000066A1 (es)
TW (1) TW201619194A (es)
WO (1) WO2016044436A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
CR20170067A (es) * 2014-09-16 2017-05-10 Ovascience Inc Anticuerpos anti-vasa y metodos de producción y uso de los mismos
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
US12534512B2 (en) 2019-11-11 2026-01-27 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefore
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) * 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
CA3009909A1 (en) 2004-05-17 2005-12-22 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
CA2544692C (en) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
MX2011003142A (es) * 2008-09-25 2011-05-19 Univ Tokyo Nat Univ Corp Anticuerpo anti-vasa de atun.
WO2010074192A1 (ja) * 2008-12-26 2010-07-01 国立大学法人東京大学 抗lgr7抗体を用いる癌の診断および治療
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
PE20141517A1 (es) 2011-04-14 2014-10-25 Gen Hospital Corp Composiciones y metodos para transferencia de energia mitocondrial de linea germinal autologa
WO2013002880A1 (en) * 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
EP2938632A4 (en) * 2012-12-31 2016-11-30 Dev Center Biotechnology ANTI-GRANULYSIN ANTIBODIES AND METHOD FOR USE THEREOF
CR20170067A (es) * 2014-09-16 2017-05-10 Ovascience Inc Anticuerpos anti-vasa y metodos de producción y uso de los mismos
US20180002662A1 (en) * 2015-01-13 2018-01-04 President And Fellows Of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
AP2017009758A0 (en) 2017-02-28
BR112017003263A2 (pt) 2017-11-28
PE20170667A1 (es) 2017-06-06
GT201700036A (es) 2018-12-19
WO2016044436A2 (en) 2016-03-24
CN106573985A (zh) 2017-04-19
WO2016044436A3 (en) 2016-06-09
PH12017500309A1 (en) 2017-07-10
AU2015317813B2 (en) 2018-04-05
ECSP17011262A (es) 2017-05-31
US20160311929A1 (en) 2016-10-27
EP3194448A4 (en) 2018-03-14
CA2959179A1 (en) 2016-03-24
MX358243B (es) 2018-08-10
AU2015317813A1 (en) 2017-03-02
SV2017005393A (es) 2017-06-07
MX2017002390A (es) 2017-07-28
CL2017000402A1 (es) 2017-11-03
US20170107299A1 (en) 2017-04-20
US20160075797A1 (en) 2016-03-17
DOP2017000050A (es) 2018-04-15
US9403913B2 (en) 2016-08-02
TW201619194A (zh) 2016-06-01
EP3194448A2 (en) 2017-07-26
SG11201701016WA (en) 2017-03-30
US20180155445A1 (en) 2018-06-07
EA201790236A1 (ru) 2017-11-30
KR20170056521A (ko) 2017-05-23
IL250451A0 (en) 2017-03-30
JP2017532953A (ja) 2017-11-09
JP2018148915A (ja) 2018-09-27
CO2017001724A2 (es) 2017-07-19
TN2017000066A1 (en) 2018-07-04
US9567404B2 (en) 2017-02-14
NI201700022A (es) 2017-05-04

Similar Documents

Publication Publication Date Title
DOP2017000050A (es) Anticuerpos anti-vasa y métodos de producción y uso de los mismos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2021003549A (es) Anticuerpos dobles especificos.
MX2017006626A (es) Cadenas ligeras comunes y metodos de uso.
MX2016016883A (es) Anticuerpo anti-axl.
MX375524B (es) Anticuerpos anti-axl.
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
CR20170203A (es) Moleculas de unión a antígeno biespecíficas activadoras de células t
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
EA201690992A1 (ru) Антитела, специфичные к fcrn
BR112015000982B8 (pt) Método para a obtenção de uma molécula de ácido nucleico sintético
BR112016019390A2 (pt) proteínas de fusão uti
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
CO2018010286A2 (es) Método para la purificación de proteínas
CL2017001633A1 (es) Método de manufactura de proteína.
MX382055B (es) Nuevo anticuerpo igf - 1r y su uso para el diagnóstico del cáncer.
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان